The prognostic significance of POD24 in peripheral T-cell lymphoma
ABSTRACTBackground: Peripheral T-cell lymphomas (PTCL) are an aggressive group of mature T-cell neoplasms, often associated with poor outcomes, in part, due to frequent relapsed/refractory disease. The objective of this study was to assess the prognostic impact of disease progression within 24 month...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Hematology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/16078454.2024.2304483 |
| _version_ | 1797349045169029120 |
|---|---|
| author | Huimin Chen Ruixue Ma Qianqian Zhang Fengyi Lu Yuhan Ma Jingxin Zhou Jiang Cao Kunming Qi Zhiling Yan Wei Sang Feng Zhu Haiying Sun Depeng Li Zhenyu Li Hai Cheng Kailin Xu Wei Chen |
| author_facet | Huimin Chen Ruixue Ma Qianqian Zhang Fengyi Lu Yuhan Ma Jingxin Zhou Jiang Cao Kunming Qi Zhiling Yan Wei Sang Feng Zhu Haiying Sun Depeng Li Zhenyu Li Hai Cheng Kailin Xu Wei Chen |
| author_sort | Huimin Chen |
| collection | DOAJ |
| description | ABSTRACTBackground: Peripheral T-cell lymphomas (PTCL) are an aggressive group of mature T-cell neoplasms, often associated with poor outcomes, in part, due to frequent relapsed/refractory disease. The objective of this study was to assess the prognostic impact of disease progression within 24 months (POD24) on overall survival (OS) for patients diagnosed with PTCL.Methods: A retrospective analysis was conducted on a cohort of patients with newly diagnosed PTCL who underwent chemotherapy at the Affiliated Hospital of Xuzhou Medical University between January 2010 and September 2021. Prognostic assessment was limited to patients who were evaluable for POD24.Results: Records were reviewed for 106 patients with PTCL, of whom 66 patients experienced POD24 (referred to as the POD24 group) and 40 patients did not experience POD24 (referred to as the no POD24 group). Significant differences were observed between the POD24 group and the no POD24 group in regard to clinical stage, Eastern Cooperative Oncology Group (ECOG) performance status (PS), International Prognostic Index (IPI) score, lactate dehydrogenase (LDH) levels, β2-microglobulin (β2-MG) levels, prealbumin and albumin levels. Patients in the POD24 group had a significant shorter median OS compared to the no POD24 group (11.9 months vs not reached, respectively; P < 0.001). Non response (NR) to treatment and POD24 were identified as independent negative prognostic factors for survival in patients with PTCL.Conclusion: POD24 is a prognostic factor associated with unfavorable outcomes in patients with PTCL and can be used to identify high-risk patients and guide treatment decisions. |
| first_indexed | 2024-03-08T12:23:25Z |
| format | Article |
| id | doaj.art-ada56b4285714342bd2679a9915c325d |
| institution | Directory Open Access Journal |
| issn | 1607-8454 |
| language | English |
| last_indexed | 2024-03-08T12:23:25Z |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Hematology |
| spelling | doaj.art-ada56b4285714342bd2679a9915c325d2024-01-22T13:33:22ZengTaylor & Francis GroupHematology1607-84542024-12-0129110.1080/16078454.2024.2304483The prognostic significance of POD24 in peripheral T-cell lymphomaHuimin Chen0Ruixue Ma1Qianqian Zhang2Fengyi Lu3Yuhan Ma4Jingxin Zhou5Jiang Cao6Kunming Qi7Zhiling Yan8Wei Sang9Feng Zhu10Haiying Sun11Depeng Li12Zhenyu Li13Hai Cheng14Kailin Xu15Wei Chen16Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People’s Republic of ChinaDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People’s Republic of ChinaDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People’s Republic of ChinaDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People’s Republic of ChinaDepartment of Hematology, The First People's Hospital of Suqian, Suqian, People’s Republic of ChinaDepartment of Hematology, The First People's Hospital of Suqian, Suqian, People’s Republic of ChinaDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People’s Republic of ChinaDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People’s Republic of ChinaDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People’s Republic of ChinaDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People’s Republic of ChinaDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People’s Republic of ChinaDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People’s Republic of ChinaDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People’s Republic of ChinaDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People’s Republic of ChinaDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People’s Republic of ChinaDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People’s Republic of ChinaDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People’s Republic of ChinaABSTRACTBackground: Peripheral T-cell lymphomas (PTCL) are an aggressive group of mature T-cell neoplasms, often associated with poor outcomes, in part, due to frequent relapsed/refractory disease. The objective of this study was to assess the prognostic impact of disease progression within 24 months (POD24) on overall survival (OS) for patients diagnosed with PTCL.Methods: A retrospective analysis was conducted on a cohort of patients with newly diagnosed PTCL who underwent chemotherapy at the Affiliated Hospital of Xuzhou Medical University between January 2010 and September 2021. Prognostic assessment was limited to patients who were evaluable for POD24.Results: Records were reviewed for 106 patients with PTCL, of whom 66 patients experienced POD24 (referred to as the POD24 group) and 40 patients did not experience POD24 (referred to as the no POD24 group). Significant differences were observed between the POD24 group and the no POD24 group in regard to clinical stage, Eastern Cooperative Oncology Group (ECOG) performance status (PS), International Prognostic Index (IPI) score, lactate dehydrogenase (LDH) levels, β2-microglobulin (β2-MG) levels, prealbumin and albumin levels. Patients in the POD24 group had a significant shorter median OS compared to the no POD24 group (11.9 months vs not reached, respectively; P < 0.001). Non response (NR) to treatment and POD24 were identified as independent negative prognostic factors for survival in patients with PTCL.Conclusion: POD24 is a prognostic factor associated with unfavorable outcomes in patients with PTCL and can be used to identify high-risk patients and guide treatment decisions.https://www.tandfonline.com/doi/10.1080/16078454.2024.2304483Peripheral T-cell lymphomaearly disease progressionPOD24POD12prognostic analysisNon-Hodgkin lymphoma |
| spellingShingle | Huimin Chen Ruixue Ma Qianqian Zhang Fengyi Lu Yuhan Ma Jingxin Zhou Jiang Cao Kunming Qi Zhiling Yan Wei Sang Feng Zhu Haiying Sun Depeng Li Zhenyu Li Hai Cheng Kailin Xu Wei Chen The prognostic significance of POD24 in peripheral T-cell lymphoma Hematology Peripheral T-cell lymphoma early disease progression POD24 POD12 prognostic analysis Non-Hodgkin lymphoma |
| title | The prognostic significance of POD24 in peripheral T-cell lymphoma |
| title_full | The prognostic significance of POD24 in peripheral T-cell lymphoma |
| title_fullStr | The prognostic significance of POD24 in peripheral T-cell lymphoma |
| title_full_unstemmed | The prognostic significance of POD24 in peripheral T-cell lymphoma |
| title_short | The prognostic significance of POD24 in peripheral T-cell lymphoma |
| title_sort | prognostic significance of pod24 in peripheral t cell lymphoma |
| topic | Peripheral T-cell lymphoma early disease progression POD24 POD12 prognostic analysis Non-Hodgkin lymphoma |
| url | https://www.tandfonline.com/doi/10.1080/16078454.2024.2304483 |
| work_keys_str_mv | AT huiminchen theprognosticsignificanceofpod24inperipheraltcelllymphoma AT ruixuema theprognosticsignificanceofpod24inperipheraltcelllymphoma AT qianqianzhang theprognosticsignificanceofpod24inperipheraltcelllymphoma AT fengyilu theprognosticsignificanceofpod24inperipheraltcelllymphoma AT yuhanma theprognosticsignificanceofpod24inperipheraltcelllymphoma AT jingxinzhou theprognosticsignificanceofpod24inperipheraltcelllymphoma AT jiangcao theprognosticsignificanceofpod24inperipheraltcelllymphoma AT kunmingqi theprognosticsignificanceofpod24inperipheraltcelllymphoma AT zhilingyan theprognosticsignificanceofpod24inperipheraltcelllymphoma AT weisang theprognosticsignificanceofpod24inperipheraltcelllymphoma AT fengzhu theprognosticsignificanceofpod24inperipheraltcelllymphoma AT haiyingsun theprognosticsignificanceofpod24inperipheraltcelllymphoma AT depengli theprognosticsignificanceofpod24inperipheraltcelllymphoma AT zhenyuli theprognosticsignificanceofpod24inperipheraltcelllymphoma AT haicheng theprognosticsignificanceofpod24inperipheraltcelllymphoma AT kailinxu theprognosticsignificanceofpod24inperipheraltcelllymphoma AT weichen theprognosticsignificanceofpod24inperipheraltcelllymphoma AT huiminchen prognosticsignificanceofpod24inperipheraltcelllymphoma AT ruixuema prognosticsignificanceofpod24inperipheraltcelllymphoma AT qianqianzhang prognosticsignificanceofpod24inperipheraltcelllymphoma AT fengyilu prognosticsignificanceofpod24inperipheraltcelllymphoma AT yuhanma prognosticsignificanceofpod24inperipheraltcelllymphoma AT jingxinzhou prognosticsignificanceofpod24inperipheraltcelllymphoma AT jiangcao prognosticsignificanceofpod24inperipheraltcelllymphoma AT kunmingqi prognosticsignificanceofpod24inperipheraltcelllymphoma AT zhilingyan prognosticsignificanceofpod24inperipheraltcelllymphoma AT weisang prognosticsignificanceofpod24inperipheraltcelllymphoma AT fengzhu prognosticsignificanceofpod24inperipheraltcelllymphoma AT haiyingsun prognosticsignificanceofpod24inperipheraltcelllymphoma AT depengli prognosticsignificanceofpod24inperipheraltcelllymphoma AT zhenyuli prognosticsignificanceofpod24inperipheraltcelllymphoma AT haicheng prognosticsignificanceofpod24inperipheraltcelllymphoma AT kailinxu prognosticsignificanceofpod24inperipheraltcelllymphoma AT weichen prognosticsignificanceofpod24inperipheraltcelllymphoma |